Phosphatidic Acids (Phosphatidic Acid)

Subscribe to Selected New Research on Phosphatidic Acids

177 relevant articles (2 outcomes, 8 trials/studies) found for this Bio-Agent

Description: Fatty acid derivatives of glycerophosphates. They are composed of glycerol bound in ester linkage with 1 mole of phosphoric acid at the terminal 3-hydroxyl group and with 2 moles of fatty acids at the other two hydroxyl groups.

Also Known As:

Phosphatidic Acid; Ammonium Phosphatidate; Diacylglycerophosphates; Acid, Phosphatidic; Acids, Phosphatidic; Phosphatidate, Ammonium

Relationship Network

Bio-Agent Context: Research Results

Lipids: 13939

Membrane Lipids: 350

Phospholipids: 3567

Glycerophosphates: 10

Phosphatidic Acids: 177

Lysophospholipids: 160

Glycerophospholipids: 90

1,2-didecanoyl-3-phosphatidic acid: 21

active pressor principle: 3

dipalmitoyl phosphatidic acid: 2

semilysobisphosphatidic acid: 2

1,2-dilauroylphosphatidic acid: 1

1-(2-nitrophenyl)ethyl-phosphatidic acid: 1

bisphosphatidic acid: 1

(GlyA-dT)10

1,2-(ditetradecyl)phosphatidic acid

1,2-dipalmitoyl glycero-3-thiophosphate

1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanol

1,2-dipalmitoyl-sn-glycerol 3-((((4-azido-2-nitrophenyl)amino)ethyl)phosphate)

1,2-dipentadecylmethylidene phosphatidic acid

1-O-(12-(N-(4-azido-2,3,5,6-tetrafluorobenzoyl))aminododecanoyl)-2-O-oleoyl-sn-glycero-3-phosphate

1-O-oleoyl-2-O-(12-(N-(azido-2,3,5,6-tetrafluorobenzoyl))aminododecanoyl)-sn-glycero-3-phosphate

1-O-palmitoyl-2-O-(12-(N-(4-azido-2,3,5,6-tetrafluorobenzoyl))aminododecanoyl)-sn-glycero-3-phosphate

1-oleoyl-2-((N-(7-(nitro)-2,1,3-benzoxadiazol-4-yl)amino)hexanoyl)glycero-3-phosphate

1-oleoyl-2-O-methyl-rac-glycerophosphothionate

1-oleoyl-2-O-methylglycerophosphothioate

1-palmitoyl-2-((2-(4-(6-phenyl-1,3,5-hexatrienyl)phenyl)ethyl)carbonyl)-3-phosphatidic acid

1-palmitoyl-2-(6-(pyren-1-yl)hexanoyl)-sn-glycero-3-phosphatidic acid

1-palmitoyl-2-oleoyl-glycero-3-phosphatidic acid

1-palmitoyl-2-oleoyl-phosphatidyl-uridine

1-stearoyl-2-arachidonoylphosphatidic acid

2,3-di-O-phytanyl-1-glycerophosphate

3-O-carba-oleoyl-cyclic phosphatidic acid

alpha-(N-acetylneuraminyl)phosphatidyloctanediol

darmstoff

dicaproylphosphatidic acid

dilauroylphosphatidic acid

dioctanoylphosphatidic acid

dioleoylphosphatidic acid

dipalmitoylphosphatidic acid

docosahexaenoylnoylphosphatidate

dodecaglycerol-adenine

dodecaglycerol-thymine

fluorescein phosphatidylethanolamine thiocarbamide

fluorescein phosphatidylethanolthiocarbamide

GlyT-(GlyA-GlyT)9

methyl 2,3,4-tri-O-acetyl-6-(1'-O-stearoyl-2'-O-acetyl-DL-glycero-3'-phosphoryl)-alpha-D-glucopyranoside ammonium salt

N(6)-(7-nitro-2,1,3-benzoxadiazol-4-yl)aminohexanoyl-1-phosphatidic acid

phosphatidic acid-beta-lactoglobulin

phosphatidylpropanol

triethylammonium 1,2-di-O-hexadecyl-glycero-3-H-phosphonate

YN emulsifier

Experts

1.	Kobayashi, Susumu: 4 articles (01/2007 - 06/2003)
2.	Murakami-Murofushi, Kimiko: 4 articles (01/2007 - 06/2003)
3.	Mukai, Mutsuko: 3 articles (01/2007 - 06/2003)
4.	Kim, Yu-Lee: 2 articles (05/2008 - 06/2007)
5.	Kim, Hyo-Lim: 2 articles (05/2008 - 06/2007)
6.	Chang, Young-Ja: 2 articles (05/2008 - 06/2007)
7.	Im, Dong-Soon: 2 articles (05/2008 - 06/2007)
8.	Tigyi, Gabor: 2 articles (01/2007 - 08/2006)
9.	Uchiyama, Ayako: 2 articles (01/2007 - 08/2006)
10.	Fujiwara, Yuko: 2 articles (01/2007 - 08/2006)

Related Diseases

1.	Neoplasms (Cancer) 10/15/1992 - "This system has been used to study the proposed role phospholipid metabolites, particularly phosphatidic acid (PA), may play (Kaszkin et al., Cancer Res., 51: 4328-4335, 1991) in the extracellular control of cells at the physiological restriction site in G2 phase. " 09/01/2009 - "Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells." 10/01/2004 - "By contrast, in platelets and some cancer cells, LPA is converted from phosphatidic acid. " 06/01/2003 - "Cyclic phosphatidic acid inhibits RhoA-mediated autophosphorylation of FAK at Tyr-397 and subsequent tumor-cell invasion." 09/15/2000 - "De novo production of phosphatidic acid (PA) in tumor cells is required for phospholipid biosynthesis and growth of tumor cells. " Order ALL the reference details at left...
2.	Neoplasm Metastasis (Metastasis) 01/01/2008 - "On the other hand, cyclic phosphatidic acids (naturally occurring analogs of LPA generated by ATX) have anti-proliferative activity and inhibit tumor cell invasion and metastasis. " 01/01/2007 - "Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid." 08/11/2006 - "Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis." 06/01/2003 - "Moreover, we reported that palmitoyl-cyclic phosphatidic acid (Pal-cPA), a structural analogue of LPA, inhibits LPA-induced migration of MM1 cells and experimental metastasis of B16 murine melanoma cells. " 06/10/2004 - "Cyclic phosphatidic acid at both dosages significantly decreased the incidence of bombesin-enhanced cancer metastases to the peritoneum but had little or no effect on the location, histologic type, depth of involvement or infiltrating growth patterns of the tumors. " Order ALL the reference details at left...
3.	Autolysis 03/01/1980 - "At the same time, an increase in lysophosphatides within 4 hr of autolysis and a decrease in concentration of phosphatidic acids within 24 hrs were found in the control group. " 03/01/1980 - "In animals with hypoxia phosphatidic acids were only slightly increased and polyglycerophosphatides were found during subsequent periods of autolysis." 09/01/1994 - "Relative content of phosphatidyl serines + sphingomyelins, phosphatidic acids + polyglycerophosphatides in grey substance as well as of phosphatidylinositides, phosphatidic acids + polyglycerophosphatides in white substance were increased, while phosphatidylinosidtides in grey substance and phosphatidyl serines + sphingomyelins in white substance were decreased within later (4 and 24 hrs) periods of autolysis. " 03/01/2004 - "The development of autolysis in grey brain matter of albino rats was accompanied by desintegration of aminophospholipids with parallel increase of glycerophosphates (GLP) and phosphatidic acids (PA) on early stages of incubation and lysophospholipids (LPL) on later stages. " 04/16/1996 - "Phosphatidyl inositol, phosphatidyl choline, phosphatidyl glycerol, phosphatidyl serine, phosphatidyl ethanolamine, phosphatidic acid and sphingomyelin were all found to be effective at reducing the Ca2+ requirement for m-calpain autolysis. " Order ALL the reference details at left...
4.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 03/01/1997 - "Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients." 03/01/1997 - "OBJECTIVE: To determine the prevalence and correlation with clinical manifestations of the IgG and IgM isotypes of antibodies to cardiolipin (aCL), phosphatidic acid (aPA), phosphatidylinositol (aPI) and phosphatidylserine (aPS) in patients with systemic lupus erythematosus (SLE). " 01/01/1991 - "The sera of systemic lupus erythematosus patients were tested by ELISA for the presence of autoantibodies against all the phospholipids: cardiolipin, phosphatidic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol and phosphatidylserine. " 02/01/2003 - "In this study, we evaluated the prevalence and association with thrombosis and/or thrombocytopenia of IgG and IgM antibodies to cardiolipin (aCL), phosphatidic acid (aPA), phosphatidylinositol (aPI), phosphatidylserine, and beta(2)-glycoprotein I (abeta(2)-GPI) in systemic lupus erythematosus (SLE). " 09/01/2008 - "PATIENTS AND METHODS: The frequency and the concentration of antibodies against cardiolipin (aCL), phosphatidylserine (aPS), phosphatidylinositol (aPI), phosphatidic acid (aPA), Beta2GPI (anti-Beta2GPI), prothrombin (aPT), annexin V (aAnnV), protein C (aPnC) and protein S (aPnS) were studied in sera from 103 children with kala-azar and compared with malaria (n=32), toxoplasmosis (n=31), systemic lupus erythematosus (SLE) (n=40) and antiphospholipid syndrome (APS) (n=35). " Order ALL the reference details at left...
5.	Breast Neoplasms (Breast Cancer) 01/01/2001 - "We previously demonstrated that phosphatidic acid (PA) induces chemotactic migration of highly metastatic breast cancer cells MDA-MB-231. " 02/16/2000 - "Enhancement of the migration of metastatic human breast cancer cells by phosphatidic acid." 02/16/2000 - "Since an enhanced ability to migrate heightens the metastatic potential of cells within solid tumors, our results suggest that the metastatic capabilities of breast cancer cells may be enhanced by a receptor-driven cellular process initiated by phosphatidic acid or related lipid phosphate messengers." 09/01/2001 - "Steady state fluorescence spectroscopy is used to study the binding characteristics of zinc phthalocyanine (ZnPc) to MCF-7 human breast cancer cells solubilized in a liposomal vesicle prepared with L-alpha-phosphatidic acid, dipalmitoyl. " 01/01/2001 - "Effect of phosphatidic acid on human breast cancer cells exposed to doxorubicin." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Phosphatidylinositols (Phosphatidylinositol)
2.	Ethanolamine (Colamine)
3.	Choline (Choline Chloride)
4.	Serine (L-Serine)
5.	Phosphatidylglycerols
6.	Bombesin
7.	m-calpain
8.	Phosphatidylcholines (Phosphatidylcholine)
9.	Cardiolipins (Cardiolipin)
10.	Phospholipase D

Related Therapies and Procedures

1.	Injections
2.	Intravenous Infusions
3.	Fluid Therapy (Oral Rehydration Therapy)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>